ArticleDisease markers2019
NK Cells as Possible Prognostic Factor in Childhood Acute Lymphoblastic Leukemia.
Article in Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Altered Expression of NK Receptors in Racially/Ethnically Diverse and Risk-of-Relapse Pediatric Acute Lymphoblastic Leukemia Patients.Biomedicines · 2025Article
- The effects of bone marrow humoral components of B-cell acute lymphoblastic leukemia patients on natural killer cell suppression.Immunologic research · 2025Article
- Distinct NK cell function and gene expression in children with acute lymphoblastic leukemia in remission before and after acute exercise: an exploratory study.Frontiers in immunology · 2025Article
- Altered immune cell profiles in blood of mature/peripheral T-cell leukemia/lymphoma patients: an EuroFlow study.Frontiers in immunology · 2025Article
- Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges.Cancers · 2024Review
- CTLA-4 Blockade of Natural Killer Cells Increases Cytotoxicity against Acute Lymphoid Leukaemia Cells Neda.Cell journal · 2024Article
- Review
- Higher baseline natural killer cell counts are associated with a lower 8-day blast count and lower day 33 minimal residual disease in children with pediatric B-acute lymphoblastic leukemia.American journal of blood research · 2023Article
- Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.Frontiers in immunology · 2023Review
- Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy.Molecular therapy oncolytics · 2022Review
- Bringing natural killer cells to the clinic.The Journal of experimental medicine · 2022Article
- Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.Biomolecules · 2022Review
- Natural Killer Cell-Mediated Immunotherapy for Leukemia.Cancers · 2022Review
- Next Generation Natural Killer Cells for Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Differential Regulation of NK Cell Receptors in Acute Lymphoblastic Leukemia.Journal of immunology research · 2022Article
- Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges.Frontiers in immunology · 2022Review
- Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives.Frontiers in immunology · 2022Review
- Review
- The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors.International journal of molecular sciences · 2021Review
- Acute lymphoblastic leukemia-derived exosome inhibits cytotoxicity of natural killer cells by TGF-β signaling pathway.3 Biotech · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deficiency or impaired function natural killer (NK) cells might result in the development of serious infections and promote the development of malignancies. The aim of our study was to assess the prognostic role of NK cell percentage in bone marrow on the day of acute lymphoblastic leukemia (ALL) diagnosis. 84 children (49 males = 58%; median age 5 yrs) with ALL were enrolled. The NK cell percentage was assessed using flow cytometry with antibodies against the cluster of differentiation (CD): CD3, CD56, and CD16. We evaluated two groups: group I (NK+), patients with NK cells in the bone marrow (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.